secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-05-27T20:07:11+00:00
Accession:  0001725160-26-000049
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Shannon Campbell as Class I director, expanding board to 7 members
--------------------------------------------------------------------------------

- Board increased from 6 to 7 directors; Campbell appointed as Class I director effective May 22, 2026.
- Annual retainer of $45,000 for board service plus $7,500 for Compensation Committee membership.
- Granted RSUs covering 114,200 shares on May 26, 2026, vesting one-third annually over three years.
- After 6 months, eligible for annual equity grant of RSUs covering 0.08% of outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/zntl-20260522.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer